Stock Analysis Report

Header cover image

Executive Summary

Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom.

Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has OptiBiotix Health's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: OPTI's share price has been volatile over the past 3 months.

Market Performance

7 Day Return




GB Biotechs


GB Market

1 Year Return




GB Biotechs


GB Market

Return vs Industry: OPTI underperformed the UK Biotechs industry which returned 15.1% over the past year.

Return vs Market: OPTI underperformed the UK Market which returned -9.5% over the past year.

Shareholder returns

7 Day-6.7%-2.4%5.5%
30 Day-4.3%8.7%10.8%
90 Day18.1%13.4%-0.4%
1 Year-32.7%-32.7%16.8%15.8%-4.8%-9.2%
3 Year-23.4%-23.4%25.7%23.4%-0.8%-12.9%
5 Year45.1%45.1%48.8%45.1%18.1%-8.2%

Price Volatility Vs. Market

How volatile is OptiBiotix Health's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is OptiBiotix Health undervalued compared to its fair value and its price relative to the market?


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OPTI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OPTI's fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: OPTI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OPTI is unprofitable, so we can't compare its PE Ratio to the UK market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPTI's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: OPTI is overvalued based on its PB Ratio (9.3x) compared to the GB Biotechs industry average (4.4x).

Next Steps

Future Growth

How is OptiBiotix Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OptiBiotix Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Next Steps

Past Performance

How has OptiBiotix Health performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OPTI is currently unprofitable.

Growing Profit Margin: OPTI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: OPTI is unprofitable, and losses have increased over the past 5 years at a rate of -8.9% per year.

Accelerating Growth: Unable to compare OPTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).

Return on Equity

High ROE: OPTI has a negative Return on Equity (-37.38%), as it is currently unprofitable.

Next Steps

Financial Health

How is OptiBiotix Health's financial position?

Financial Position Analysis

Short Term Liabilities: OPTI's short term assets (£1.3M) exceed its short term liabilities (£561.6K).

Long Term Liabilities: OPTI's short term assets (£1.3M) exceed its long term liabilities (£1.2M).

Debt to Equity History and Analysis

Debt Level: OPTI's debt to equity ratio (13.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if OPTI's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OPTI has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: OPTI is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.

Next Steps


What is OptiBiotix Health's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPTI's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OPTI's dividend in 3 years as they are not forecast to pay a notable one for the UK market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Stephen O'Hara

no data




Mr. Stephen Patrick O'Hara Founded OptiBiotix Health plc in March 2012 and serves as its Chief Executive. He also serves as the Board Director of ProBiotix Health Limited. Mr. O'Hara served as the Chief Ex ...

CEO Compensation Analysis

Compensation vs Market: Stephen's total compensation ($USD288.07K) is about average for companies of similar size in the UK market ($USD341.60K).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.

Board Members

Stephen O'Hara
Founderno dataUK£228.90k11.49% £5.6m
Sofia Kolida
Director of Research & Development and Executive Director1.92yrsUK£113.41kno data
Frederic Narbel
Executive Director & Managing Director of Prebiotics Division1.25yrsUK£204.84k0.062% £30.4k
Stephen Prescott
Executive Directorno dataUK£116.97kno data
Sean Christie
Non-Executive Director1.75yrsUK£40.43k0.14% £69.4k
Tim Spector
Member of Scientific Advisory Group4.42yrsno datano data
Neil Davidson
Non-Executive Chairman2.42yrsUK£94.48k0.54% £265.3k
Jan Peter Wennström
Non-Executive Director4.58yrsUK£19.55kno data


Average Tenure


Average Age

Experienced Board: OPTI's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: OPTI insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.

Top Shareholders

Company Information

OptiBiotix Health Plc's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: OptiBiotix Health Plc
  • Ticker: OPTI
  • Exchange: AIM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£48.807m
  • Shares outstanding: 87.94m
  • Website:

Number of Employees


  • OptiBiotix Health Plc
  • Innovation Centre
  • Innovation Way
  • York
  • North Yorkshire
  • YO10 5DG
  • United Kingdom


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OPTIAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPAug 2014
OPTIAIM (London Stock Exchange AIM Market)ORD GBP0.02GBGBPNov 2016
OB3DB (Deutsche Boerse AG)ORD GBP0.02DEEURNov 2016


Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, an ingredient for use in a range of functional food products and supplements in consumer and pharmaceutical health care; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galacto oligosaccharide that are used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company’s products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 23:12
End of Day Share Price2020/06/05 00:00
Annual Earnings2019/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.